Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Warner Chilcott Limited, a specialty pharmaceutical company, has announced that its subsidiary Warner Chilcott Company, Inc and Barr Laboratories, a subsidiary of Barr Pharmaceuticals, have entered into a settlement and licensing agreement to resolve the pending patent litigation involving Warner Chilcott's oral contraceptive product, Femcon Fe.
Subscribe to our email newsletter
Under the terms of the agreement, Barr will have a license to launch a generic version of Femcon Fe as early as July 1, 2012, approximately seven years earlier than the expiration of the Warner Chilcott patent at issue in the litigation, or earlier in certain circumstances.
Barr will pay Warner Chilcott a royalty on net sales of Barr’s generic product. The parties said that the filing of a dismissal without prejudice in the US District Court of New Jersey concludes this litigation.